CRBN-based selective IKZF1/3 degrader
oral efficacy in lenalidomide-resist. xenograft
from phenotypic screen and optimization
J. Med. Chem., Mar. 4, 2020
Celgene, San Diego, CA
CC-92480
1 min read
CC-92480 (Celgene/Bristol Myers Squibb (BMS) oral in vivo CRBN-based selective IKZF1/3 degrader)
Search By Structure
- CC-92480
- “PROTAC 6”
- GSK620
- Merck hArg1 inhibitor
- Merck IDO1 inhibitor
- Constellation EZH2 inhibitor
- Arcus CD73 inhibitor
- MK-6884
- Sulfopin
- M3814
- Remibrutinib
Molecules of the Month
2023
2022
2021
2020